Ensemble Therapeutics Presents Oral Efficacy

Ensemble Therapeutics Presents Oral Efficacy of First-in-Class Small Molecule Targeting IL-17 for Inflammation in Preclinical Studies

CAMBRIDGE, Mass., Nov 12, 2012 (BUSINESS WIRE) — –On Track to Select Orally Active IL-17 Drug Candidate in early 2013

Ensemble Therapeutics, a biotechnology company developing Ensemblins(TM), a novel class of small molecule therapeutics with the power of biologics, announced today positive preclinical oral efficacy data with its first-in-class small molecule Interleukin-17 (IL-17) antagonists. A presentation at the American College of Rheumatology (ACR) 2012 Annual Meeting, taking place November 9-14, 2012 in Washington, DC, revealed that the company’s Ensemblins have strong as antagonists of IL-17, a pro-inflammatory implicated in multiple inflammatory and such as , , Crohn’s disease and .

“We have made dramatic progress since the first announcement of our small molecule IL-17 antagonist program earlier this year,” said Dr. Michael D. Taylor, CEO of Ensemble Therapeutics. “This data is compelling in showing excellent oral efficacy in vivo for several lead molecules, which puts us solidly on track to nominate an oral drug candidate for clinical development early in 2013.”

Read Full

Ensemble Therapeutics Presents Oral Efficacy of First-in-Class Small Molecule
MarketWatch (press release)
the company’s Ensemblins have strong oral activity as antagonists of IL-17, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn’s disease and inflammatory bowel disease.and more »

Leave a Reply